Mark J Newman , Dennis McKinney , Robert Chesnut , Alessandro Sette , Cara Wilson , Brian Livingston
{"title":"基于t淋巴细胞表位的治疗性HIV-1疫苗的设计与构建","authors":"Mark J Newman , Dennis McKinney , Robert Chesnut , Alessandro Sette , Cara Wilson , Brian Livingston","doi":"10.1016/S1529-1049(02)00161-7","DOIUrl":null,"url":null,"abstract":"<div><p>The demonstration that highly active anti-retroviral therapy (HAART) can control human immunodeficiency virus type 1<span> (HIV-1) viral replication and the associated destruction of the immune system provides an opportunity to implement therapeutic vaccine strategies. The Epimmune approach is based on separate vaccine immunogens designed to induce, or augment, helper T-lymphocyte (HTL) or cytotoxic T-lymphocyte (CTL) responsiveness when administered in conjunction with HAART. The vaccines are composed of carefully selected, minimal HTL or CTL epitopes. Vaccines composed of multiple epitopes can be produced and delivered using different formats, including deoxyribonucleic acid (DNA) plasmid-based vaccines and recombinant proteins.</span></p></div>","PeriodicalId":89340,"journal":{"name":"Clinical and applied immunology reviews","volume":"3 4","pages":"Pages 157-166"},"PeriodicalIF":0.0000,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1529-1049(02)00161-7","citationCount":"0","resultStr":"{\"title\":\"Design and construction of T-lymphocyte epitope-based therapeutic HIV-1 vaccines\",\"authors\":\"Mark J Newman , Dennis McKinney , Robert Chesnut , Alessandro Sette , Cara Wilson , Brian Livingston\",\"doi\":\"10.1016/S1529-1049(02)00161-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>The demonstration that highly active anti-retroviral therapy (HAART) can control human immunodeficiency virus type 1<span> (HIV-1) viral replication and the associated destruction of the immune system provides an opportunity to implement therapeutic vaccine strategies. The Epimmune approach is based on separate vaccine immunogens designed to induce, or augment, helper T-lymphocyte (HTL) or cytotoxic T-lymphocyte (CTL) responsiveness when administered in conjunction with HAART. The vaccines are composed of carefully selected, minimal HTL or CTL epitopes. Vaccines composed of multiple epitopes can be produced and delivered using different formats, including deoxyribonucleic acid (DNA) plasmid-based vaccines and recombinant proteins.</span></p></div>\",\"PeriodicalId\":89340,\"journal\":{\"name\":\"Clinical and applied immunology reviews\",\"volume\":\"3 4\",\"pages\":\"Pages 157-166\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2003-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/S1529-1049(02)00161-7\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and applied immunology reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1529104902001617\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and applied immunology reviews","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1529104902001617","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Design and construction of T-lymphocyte epitope-based therapeutic HIV-1 vaccines
The demonstration that highly active anti-retroviral therapy (HAART) can control human immunodeficiency virus type 1 (HIV-1) viral replication and the associated destruction of the immune system provides an opportunity to implement therapeutic vaccine strategies. The Epimmune approach is based on separate vaccine immunogens designed to induce, or augment, helper T-lymphocyte (HTL) or cytotoxic T-lymphocyte (CTL) responsiveness when administered in conjunction with HAART. The vaccines are composed of carefully selected, minimal HTL or CTL epitopes. Vaccines composed of multiple epitopes can be produced and delivered using different formats, including deoxyribonucleic acid (DNA) plasmid-based vaccines and recombinant proteins.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
